Karen L. Smith - 12 Jun 2025 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role
Director
Signature
/s/ Prathyusha Duraibabu, Attorney-in-Fact
Issuer symbol
SGMO
Transactions as of
12 Jun 2025
Net transactions value
$0
Form type
4
Filing time
16 Jun 2025, 16:05:23 UTC
Previous filing
26 Feb 2025
Next filing
09 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Smith Karen L. Director C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND /s/ Prathyusha Duraibabu, Attorney-in-Fact 16 Jun 2025 0001639637

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMO Common Stock Award $0 +25,000 +32% $0.000000 102,100 12 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGMO Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 12 Jun 2025 Common Stock 50,000 $0.5030 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
F2 The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.